Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

Pediatric Reports

Volumn 3, Issue 2S, 2011, Pages 43-47

  Munchel, Ashley ^a   Kesserwan, Chimen ^a   Symons, Heather J ^a   Luznik, Leo ^a   Kasamon, Yvette L ^a   Jones, Richard J ^a   Fuchs, Ephraim J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

HLA haploidentical bone marrow transplantation

Indexed keywords

EID: 82955209267     PISSN: None     EISSN: 20367503     Source Type: Journal    
DOI: 10.4081/pr.2011.s2.e15     Document Type: Article

References (24)

1. Schwartz R, Dameshek W. Drug-induced immunological tolerance. Nature 1959; 183:1682-3.
2. Berenbaum MC, Brown IN. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 1963; 200:84.
3. Nirmul G, Severin C, Taub RN. Cyclophosphamide- induced immunologic tolerance to skin homografts. Surg Forum 1971;22:287-8.
4. Mayumi H, Himeno K, Shin T, Nomoto K. Drug-induced tolerance to allografts in mice. VI. Tolerance induction in H-2-haplotype- identical strain combinations in mice. Transplantation 1985;40:188-94.
5. Eto M, Mayumi H, Tomita Y, et al. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol 1990;145:1303-10.
6. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002;128:255-66.
7. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002;8:377-386.
8. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641-50.
9. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biol. Blood Marrow Transplant 2010;16:482-9.
10. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versushost disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29:79-91.
11. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997;15:1767-77.
12. Ash RC, Horowitz MM, Gale RP, et al. Bone marrow transplantation from related donors other than HLA- identical siblings: effect of T cell depletion. Bone Marrow Transplant 1991;7:443-52.
13. Symons HJ, Leffell MS, Rossiter ND, et al. Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 2010;16:533-42.
14. Mayumi H, Good RA. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. J Exp Med 1989;169:213-38.
15. Mayumi H, Umesue M, Nomoto K. Cyclophosphamide- induced immunological tolerance: an overview. Immunobiology 1996;195:129-39.
16. Colson YL, Li H, Boggs SS, et al. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996;157:2820-9.
17. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001;98:3456-64.
18. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
19. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
20. Mentzer WC, Heller S, Pearle PR, et al. Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol 1994;16:27-9.
21. Hutter G, Nowak D, Mossner M, et al. Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. N Engl J Med 2009;360:692-8.
22. Allers K, Hutter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5{Delta}32/{Delta}32 stem cell transplantation. Blood 2011;117:2791-9.
23. Luznik L, Fuchs E. High-dose, post-transplantation cyclophosphamide to promote graft- host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010;47:65-77.
24. Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010;17:493-9.